Press Releases

Our press releases

• Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock Feb 18 2021
• Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock Feb 16 2021
• Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock Feb 13 2021
• Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology Feb 10 2021
• Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002 Nov 19 2020
• BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS Nov 13 2020
• Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020 Nov 6 2020
• Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers Oct 22 2020
• Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Sep 9 2020
• BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Aug 14 2020